EDSA News and Press, Edesa Biotech Inc. From 02/13/20

TORONTO, ON / ACCESSWIRE / February 13, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three months ended December 31, 2019 and provided an update on its business. During the quarter, Edesa expanded an ongoing P...

Gainers:  aTyr Pharma (NASDAQ: LIFE )  +48% . More news on: aTyr Pharma, Inc., Mechel PAO, The Habit Restaurants, Inc., Stocks on the move, Read more ...

Thinly traded nano cap Edesa Biotech ( EDSA -22.6% ) slumps on triple normal volume, albeit a modest 76K shares, in reaction to its direct offering of ~1.4M common shares at $3.20 per share (investors who are affiliated with the company will pay $4.11 per share). More news on: Edesa Bi...

TORONTO, ON / ACCESSWIRE / January 6, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive securities purchase agreements with certain institutional and accredited investors as well as company insiders in a...

Edesa Biotech (NASDAQ: EDSA ): 9M GAAP EPS of -$0.55. More news on: Edesa Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

TORONTO, ON / ACCESSWIRE / December 12, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the nine-month period ended September 30, 2019 and provided an update on its business. Edesa recently enrolled the first patient...

TORONTO, ON / ACCESSWIRE / December 3, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported that the company's lead product candidate, EB01, has demonstrated positive safety data in healthy volunteers participating in its ongoing Phase 2b clini...

TORONTO, ON / ACCESSWIRE / November 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that its management will present at the H.C. Wainwright 5th Annual Israel Conference in Tel Aviv, Israel. The company is scheduled to participate in a...

A first patient has been enrolled in Edesa Biotech's (NASDAQ: EDSA ) Phase 2b clinical trial evaluating EB01, as a monotherapy for patients with moderate to severe chronic allergic contact dermatitis (ACD). More news on: Edesa Biotech, Inc., Healthcare stocks news, Read more ...

TORONTO, ON / ACCESSWIRE / October 21, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the company's lead product candidate, EB01, as a monotherapy for patie...